Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reengineering the specificity of the highly selective Clostridium botulinum protease via directed evolution.
Dyer RP, Isoda HM, Salcedo GS, Speciale G, Fletcher MH, Le LQ, Liu Y, Brami-Cherrier K, Malik SZ, Vazquez-Cintron EJ, Chu AC, Rupp DC, Jacky BPS, Nguyen TTM, Katz BB, Steward LE, Majumdar S, Brideau-Andersen AD, Weiss GA. Dyer RP, et al. Among authors: fletcher mh. Sci Rep. 2022 Jun 15;12(1):9956. doi: 10.1038/s41598-022-13617-z. Sci Rep. 2022. PMID: 35705606 Free PMC article.
Natural Products as Platforms To Overcome Antibiotic Resistance.
Rossiter SE, Fletcher MH, Wuest WM. Rossiter SE, et al. Among authors: fletcher mh. Chem Rev. 2017 Oct 11;117(19):12415-12474. doi: 10.1021/acs.chemrev.7b00283. Epub 2017 Sep 27. Chem Rev. 2017. PMID: 28953368 Free PMC article. Review.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
31 results